Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz